+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PTC Therapeutics - logo

PTC Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product candidate is Translarna (ataluren), which is for the treatment of of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is currently in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Rett Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Rett Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Ataxia - Pipeline Insight, 2025 - Product Thumbnail Image

Ataxia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 152 Pages
  • Global
From
Angelman Syndrome - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Angelman Syndrome - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • June 2024
  • 200 Pages
  • Global
From
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • June 2024
  • 200 Pages
  • Global
From
Amyotrophic Lateral Sclerosis (ALS) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis (ALS) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • March 2024
  • 267 Pages
  • Global
From
Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 532 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Report and Forecast 2024-2032 - Product Thumbnail Image

Spinal Muscular Atrophy Treatment Market Report and Forecast 2024-2032

  • Report
  • October 2024
  • 250 Pages
  • Global
From
Drug Resistant Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Drug Resistant Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Friedreich Ataxia - Pipeline Insight, 2025 - Product Thumbnail Image

Friedreich Ataxia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Leiomyosarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Leiomyosarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030 - Product Thumbnail Image

Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • Report
  • August 2022
  • 115 Pages
  • Global
From
Leigh Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Leigh Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Transforming Growth Factor (TGF) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Transforming Growth Factor (TGF) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 871 Pages
  • Global
From
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1036 Pages
  • Global
From
Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 106 Pages
  • Global
From
Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 138 Pages
  • Global
From
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1560 Pages
  • Global
From
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 820 Pages
  • Global
From
Loading Indicator